News 28.05.2025 CUTISS has completed an interim analysis in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns, with positive results. The randomized, controlled trial enrolled 12 pediatric patients, comparing denovoSkin™ to the current standard of care (autografting) using an intra-patient control design. The results from...
News 28.05.2025 Newton, MA & Wädenswil, Switzerland – May 27, 2025– GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, today announced the closing of an oversubscribed $130 million Series B financing. The proceeds will be used to advance the Company’s lead IgG4-targeted protein degrader...
News 20.05.2025 WASHINGTON, D.C. and ZUERICH, Switzerland – May 19, 2025 – (GlobeNewswire) – SISCAPA Assay Technologies, a global leader in high-sensitivity protein quantitation, and Biognosys, a pioneer in next-generation proteomics, today announced an exclusive strategic collaboration to offer biopharma customers a streamlined end-to-end solution for high-sensitivity protein analysis—from early protein biomarker and drug target discovery, all...
News 16.05.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...
News 15.05.2025 According to a press release, the Schlieren-based biotech company Biognosys has fully equipped the first laboratory in Europe with its P2 plasma enrichment system. The system has been installed at the Proteomics Core Facility at the University of Gothenburg. This is an important step in making Biognosys' P2 technology more...